This inventor holds 2 USPTO granted patents. Top assignee: University of Connecticut. Active years: 2014-2020.
Location History:
- Vernon, CT (US) (2014)
- Mansfield Center, CT (US) (2020)
Company Filing History:
Years Active: 2014-2020
Title: Eric William Scocchera: Innovator in Antifolate Research
Introduction
Eric William Scocchera is a notable inventor based in Vernon, Connecticut. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that target bacterial infections. With a total of 2 patents, his work is recognized for its potential impact on treating various infections.
Latest Patents
Scocchera's latest patents include innovative compounds designed to combat bacterial infections. One of his patents, titled "Zwitterionic propargyl-linked antifolates useful for treating bacterial infections," discloses compounds that can inhibit dihydrofolate reductase (DHFR) in vitro or in vivo. This patent outlines pharmaceutical compositions that include these compounds and methods for treating bacterial, fungal, and protozoal infections. Another significant patent is focused on "Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase." This work details the design and synthesis of potent inhibitors that are selective for various pathogenic organisms, including methicillin-resistant bacteria and certain fungi.
Career Highlights
Eric William Scocchera is affiliated with the University of Connecticut, where he conducts his research. His work has garnered attention for its innovative approach to addressing critical health challenges through the development of new therapeutic agents.
Collaborations
Some of his notable coworkers include Amy C. Anderson and Dennis L. Wright. Their collaborative efforts contribute to the advancement of research in the field of antifolate compounds.
Conclusion
Eric William Scocchera's contributions to pharmaceutical research highlight his role as an innovator in the development of treatments for bacterial infections. His patents reflect a commitment to advancing medical science and improving health outcomes.